Holen Sie sich die Stockscreener-App
0.1111
4.72%
-0.0055
Handel nachbörslich:
.12
0.0089
+8.01%
Schlusskurs vom Vortag:
$0.1166
Offen:
$0.11
24-Stunden-Volumen:
2.31M
Relative Volume:
2.05
Marktkapitalisierung:
$7.12M
Einnahmen:
$1.47M
Nettoeinkommen (Verlust:
$-97.61M
KGV:
-0.0746
EPS:
-1.49
Netto-Cashflow:
$-80.90M
1W Leistung:
-27.24%
1M Leistung:
-42.85%
6M Leistung:
-51.76%
1J Leistung:
-97.97%
1-Tages-Spanne:
$0.1021
$0.1162
1-Wochen-Bereich:
$0.1021
$0.155
52-Wochen-Spanne:
$0.1021
$5.77
Lyra Therapeutics Inc Stock (LYRA) Company Profile
Firmenname
Lyra Therapeutics Inc
Sektor
Branche
Telefon
617-373-4600
Adresse
480 ARSENAL WAY, WATERTOWN, MA
Vergleichen Sie LYRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LYRA
Lyra Therapeutics Inc
|
0.1111 | 7.12M | 1.47M | -97.61M | -80.90M | -1.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 125.55B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 67.78B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 36.24B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.99B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.77B | 3.81B | -644.79M | -669.77M | -6.24 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-07 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-05-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-05-07 | Herabstufung | Jefferies | Buy → Hold |
| 2024-05-06 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-06 | Fortgesetzt | BTIG Research | Buy |
| 2023-08-31 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-05-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-05-26 | Eingeleitet | BTIG Research | Buy |
| 2020-05-26 | Eingeleitet | BofA/Merrill | Buy |
| 2020-05-26 | Eingeleitet | Jefferies | Buy |
| 2020-05-26 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Lyra Therapeutics Inc Aktie (LYRA) Neueste Nachrichten
Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates - Nasdaq
Lyra Therapeutics stock hits 52-week low at $0.14 amid sharp decline By Investing.com - Investing.com South Africa
Lyra Therapeutics stock hits 52-week low at $0.14 amid sharp decline - Investing.com Australia
Lyra Therapeutics stock plunges to 52-week low of $0.16 By Investing.com - Investing.com Australia
Lyra Therapeutics stock plunges to 52-week low of $0.16 - Investing.com India
Analysts Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) Target Price at $4.50 - Defense World
Analysts Set TScan Therapeutics, Inc. (NASDAQ:TCRX) PT at $9.33 - Defense World
Lyra Therapeutics (NASDAQ:LYRA) Earns “Neutral” Rating from HC Wainwright - Defense World
Lyra Therapeutics Reports 2024 Financial Results and Updates - TipRanks
Arbor Realty Trust Closes a $1.15 Billion Repurchase Facility to Unwind Two Outstanding Collateralized Loan Obligations - The Manila Times
Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
FDA Green Light: Lyra's Nasal Polyp Treatment Advances as 52-Week Data Shows Promise - StockTitan
Lyra Therapeutics reports Q4 EPS ($1.43), consensus (13c) - TipRanks
Lyra Therapeutics (LYRA) to Release Quarterly Earnings on Thursday - Defense World
Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Layoff Tracker: Atea Pharmaceuticals Cuts 25% of Workforce - BioSpace
Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions - Bain Capital
Lyra Therapeutics Inc (LYRA) expanding its growth trajectory ahead - SETE News
Chronic Rhinosinusitis Pipeline 2024: FDA Updates, Therapy - openPR.com
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates - Nasdaq
Dream Finders Homes (NASDAQ:DFH) Shares Gap Up Following Better-Than-Expected Earnings - Defense World
Comparing Lyra Therapeutics (NASDAQ:LYRA) & Anika Therapeutics (NASDAQ:ANIK) - Defense World
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down on Disappointing Earnings - Defense World
Head to Head Analysis: Kymera Therapeutics (NASDAQ:KYMR) and Creative Medical Technology (NASDAQ:CELZ) - Defense World
Watch this stock’s price performance: Lyra Therapeutics Inc (NASDAQ:LYRA) - US Post News
Lyra Therapeutics Inc (LYRA) receives a Hold rating from Jefferies - Knox Daily
Examining the Potential Price Growth of Oshkosh Corp (OSK) - Knox Daily
Neuronetics Inc [STIM] Stock sold by Insider Furlong Stephen for $1122.0 - Knox Daily
BrightSpire Capital Inc [BRSP] Insider Activity: An Update for Investors - Knox Daily
LYRA’s 2023 Market Dance: Down -5.96% – Time to Invest? - The InvestChronicle
Lyra Therapeutics Inc (LYRA) Shares Rise Despite Market Challenges - The News Heater
TD Cowen Initiates Coverage on Palvella Therapeutics (NASDAQ:PVLA) - Defense World
Deeper Dive: Understanding Immunome Inc (IMNM) Through its Various Ratios - The Dwinnex
LYRA News Today | Why did Lyra Therapeutics stock go up today? - MarketBeat
Selling Your Galaxy Payroll Group Ltd (GLXG) Stock? Here’s What You Need To Know - Stocks Register
New Outlook On ReNew Energy Global plc - Stocks Register
Open Lending Corp’s (LPRO) Stock Is Harder To Predict Than You Think - Stocks Register
There Is A Lot Of Upside Potential For Helius Medical Technologies Inc(NASDAQ: HSDT) - Stocks Register
New Outlook On Vestis Corp - Stocks Register
Data-Based Insights About MINISO Group Holding Ltd ADR (MNSO) - Stocks Register
Lyra Therapeutics (LYRA) Upgraded to Strong Buy: Here's What You Should Know - MSN
Chronic Rhinosinusitis Without Nasal Polyps Therapeutics - openPR
Revance Therapeutics jumps after Teoxane offers $3.60 a share - MSN
Cidara Therapeutics Announces Leadership Changes and Appointments - MSN
Are Investors Keen On Selling Holdings In Phoenix Motor Inc (NASDAQ: PEV)? - Stocks Register
State Street Corp Takes Position in Lotus Technology Inc. (NASDAQ:LOT) - Defense World
Finanzdaten der Lyra Therapeutics Inc-Aktie (LYRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):